{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:13:57Z","timestamp":1792710837023,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","gastro.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.gtc.2015.05.003","type":"journal-article","created":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T05:33:04Z","timestamp":1434691984000},"page":"537-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"title":["How to Effectively Use Bismuth Quadruple Therapy"],"prefix":"10.1016","volume":"44","author":[{"given":"David Y.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2015.05.003_bib1","series-title":"A\u00a0treatise of the materia medica and therapeutics","author":"Eberle","year":"1834"},{"key":"10.1016\/j.gtc.2015.05.003_bib2","first-page":"1125","article-title":"Ulcer of the stomach successfully treated","volume":"3","author":"Brinton","year":"1855","journal-title":"Assoc Med J"},{"key":"10.1016\/j.gtc.2015.05.003_bib3","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.4155\/fmc.12.95","article-title":"Bismuth compounds in medicinal chemistry","volume":"4","author":"Salvador","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.gtc.2015.05.003_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/106002808702100901","article-title":"Bismuth subsalicylate in the treatment and prevention of diarrheal disease","volume":"21","author":"DuPont","year":"1987","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1016\/j.gtc.2015.05.003_bib5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0016-5085(83)80066-3","article-title":"Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers","volume":"85","author":"Graham","year":"1983","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2015.05.003_bib6","first-page":"233","article-title":"In\u00a0vivo susceptibility of Campylobacter pylori","volume":"84","author":"Graham","year":"1989","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2015.05.003_bib7","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/clinids\/12.Supplement_1.S68","article-title":"Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers","volume":"12","author":"Graham","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.gtc.2015.05.003_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/00365528909091043","article-title":"Review of the modes of action of colloidal bismuth subcitrate","volume":"157","author":"Hall","year":"1989","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gtc.2015.05.003_bib9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S0016-5085(82)80247-3","article-title":"Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat","volume":"82","author":"Koo","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2015.05.003_bib10","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1023\/A:1026667714603","article-title":"Chemical structure of bismuth compounds determines their gastric ulcer healing efficacy and anti-Helicobacter pylori activity","volume":"43","author":"Sandha","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2015.05.003_bib11","first-page":"11","article-title":"Pharmacological properties of colloidal bismuth subcitrate (CBS, DE-NOL)","volume":"80","author":"Wieriks","year":"1982","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gtc.2015.05.003_bib12","first-page":"107","article-title":"Helicobacter pylori","volume":"vol. 99","author":"Borsch","year":"1991"},{"issue":"Suppl 8","key":"10.1016\/j.gtc.2015.05.003_bib13","doi-asserted-by":"crossref","first-page":"S691","DOI":"10.1093\/clinids\/13.Supplement_8.S691","article-title":"Pharmacology of bismuth-containing compounds","volume":"13","author":"Lambert","year":"1991","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.gtc.2015.05.003_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(87)91545-5","article-title":"Campylobacter pylori and recurrence of duodenal ulcers\u2013a 12-month follow-up study","volume":"2","author":"Coghlan","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2015.05.003_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(81)90114-8","article-title":"Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate","volume":"1","author":"Martin","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2015.05.003_bib16","first-page":"23","article-title":"A\u00a0comparative study of colloidal bismuth subcitrate and cimetidine on the healing and recurrence of duodenal ulcer","volume":"80","author":"Vantrappen","year":"1982","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gtc.2015.05.003_bib17","first-page":"39","article-title":"Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate","volume":"80","author":"Miller","year":"1982","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gtc.2015.05.003_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000198690","article-title":"Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer. Comparison of initial healing and recurrence after healing","volume":"23","author":"Kang","year":"1982","journal-title":"Digestion"},{"key":"10.1016\/j.gtc.2015.05.003_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000198970","article-title":"Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers","volume":"28","author":"Shreeve","year":"1983","journal-title":"Digestion"},{"key":"10.1016\/j.gtc.2015.05.003_bib20","first-page":"698","article-title":"Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine","volume":"2","author":"Bianchi","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2015.05.003_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/gut.27.1.106","article-title":"Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine","volume":"27","author":"Hamilton","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2015.05.003_bib22","first-page":"35","article-title":"The influence of colloidal bismuth subcitrate on duodenal ulcer relapse","volume":"122","author":"Bianchi","year":"1986","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.gtc.2015.05.003_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-116-9-705","article-title":"Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study","volume":"116","author":"Graham","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2015.05.003_bib24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5694\/j.1326-5377.1989.tb101251.x","article-title":"Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication","volume":"151","author":"Borody","year":"1989","journal-title":"Med J Aust"},{"key":"10.1016\/j.gtc.2015.05.003_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5694\/j.1326-5377.1990.tb136833.x","article-title":"Cure of duodenal ulcer after eradication of Helicobacter pylori","volume":"153","author":"George","year":"1990","journal-title":"Med J Aust"},{"key":"10.1016\/j.gtc.2015.05.003_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/gut.37.4.477","article-title":"Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori","volume":"37","author":"Borody","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2015.05.003_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(95)92962-2","article-title":"Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection","volume":"345","author":"de Boer","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2015.05.003_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2036.1994.tb00285.x","article-title":"Short report: omeprazole-tetracycline combinations are inadequate as therapy for Helicobacter pylori infection","volume":"8","author":"Al-Assi","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1046\/j.1365-2036.2000.00770.x","article-title":"Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study","volume":"14","author":"Graham","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1523-5378.2009.00735.x","article-title":"Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea","volume":"15","author":"Lee","year":"2010","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ije\/31.1.128","article-title":"Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis","volume":"31","author":"Fischbach","year":"2002","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.gtc.2015.05.003_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","article-title":"Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies","volume":"20","author":"Fischbach","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib33","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0002-9270(99)00258-0","article-title":"The influence of in\u00a0vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis","volume":"94","author":"van der Wouden","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1523-5378.2000.00030.x","article-title":"The HOMER study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection","volume":"5","author":"Bardhan","year":"2000","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1523-5378.2003.00158.x","article-title":"A\u00a0prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"8","author":"Miehlke","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib36","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","article-title":"Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori","volume":"26","author":"Fischbach","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/17474124.2014.859522","article-title":"Evidence-based recommendations for successful Helicobacter pylori treatment","volume":"8","author":"Wu","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1590-8658(04)00085-4","article-title":"Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States","volume":"36","author":"Graham","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gtc.2015.05.003_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0924-8579(00)00320-4","article-title":"Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori","volume":"17","author":"Osato","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.gtc.2015.05.003_bib42","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2015.05.003_bib43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1523-5378.2012.00962.x","article-title":"Greater than 95% success with 14-day bismuth quadruple anti-Helicobacter pylori therapy: a pilot study in US Hispanics","volume":"17","author":"Salazar","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib44","first-page":"33","article-title":"Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori","volume":"89","author":"Borody","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00004836-199606000-00016","article-title":"How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint","volume":"22","author":"de Boer","year":"1996","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.0306-5251.2001.01531.x","article-title":"Management of Helicobacter pylori eradication\u2013the influence of structured counselling and follow-up","volume":"53","author":"Al-Eidan","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.gtc.2015.05.003_bib47","doi-asserted-by":"crossref","first-page":"7361","DOI":"10.3748\/wjg.14.7361","article-title":"Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis","volume":"14","author":"Ford","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib48","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","article-title":"Triple vs quadruple therapy for treating Helicobacter pylori infection: a meta-analysis","volume":"17","author":"Gene","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib49","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/003655201300191941","article-title":"Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection","volume":"36","author":"Hojo","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/apt.12808","article-title":"Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori","volume":"40","author":"Delchier","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib51","series-title":"Helicobacter pylori basic mechanisms to clinical cure 1998","first-page":"426","article-title":"Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis","author":"Graham","year":"1998"},{"key":"10.1016\/j.gtc.2015.05.003_bib52","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1572-0241.2002.05600.x","article-title":"Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection","volume":"97","author":"Dore","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1523-5378.2003.00150.x","article-title":"Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen","volume":"8","author":"Dore","year":"2003","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1523-5378.2011.00857.x","article-title":"Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days","volume":"16","author":"Dore","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.0083-8703.2006.00370.x","article-title":"Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly","volume":"11","author":"Dore","year":"2006","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib56","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1365-2036.1997.00219.x","article-title":"Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection","volume":"11","author":"Graham","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib57","first-page":"8","article-title":"Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infections: a single-center, randomized, open and parallel-controlled study","volume":"14","author":"Zheng","year":"2009","journal-title":"Chin J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib58","first-page":"313","article-title":"Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance","volume":"11","author":"Zheng","year":"2010","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.gtc.2015.05.003_bib59","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/00042737-200012120-00008","article-title":"Limited usefulness of a seven-day twice-a-day quadruple therapy","volume":"12","author":"Garcia","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/00365529209000075","article-title":"Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy","volume":"27","author":"Borody","year":"1992","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2036.2004.01910.x","article-title":"High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection","volume":"19","author":"Cammarota","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib62","first-page":"273","article-title":"Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients","volume":"53","author":"Wang","year":"2012","journal-title":"Singapore Med J"},{"key":"10.1016\/j.gtc.2015.05.003_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12209","article-title":"A\u00a0triple and quadruple therapy with doxycycline and bismuth for first-line treatment of Helicobacter pylori infection: a pilot study","author":"Ciccaglione","year":"2015","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib64","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/0255-0857.37342","article-title":"Antimicrobial susceptibility testing of Helicobacter pylori to selected agents by agar dilution method in Shiraz-Iran","volume":"25","author":"Kohanteb","year":"2007","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.gtc.2015.05.003_bib65","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3748\/wjg.v10.i5.668","article-title":"Low eradication rate of Helicobacter pylori with triple 7\u201314 days and quadruple therapy in Turkey","volume":"10","author":"Gumurdulu","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib66","first-page":"90","article-title":"Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy","volume":"15","author":"Altintas","year":"2004","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib67","first-page":"211","article-title":"The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori","volume":"8","author":"Uygun","year":"2007","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.gtc.2015.05.003_bib68","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MAJ.0b013e31819c7320","article-title":"Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment","volume":"338","author":"Songur","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.gtc.2015.05.003_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000236024","article-title":"Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients","volume":"82","author":"Demir","year":"2010","journal-title":"Digestion"},{"key":"10.1016\/j.gtc.2015.05.003_bib70","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.clinthera.2008.03.009","article-title":"Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia","volume":"30","author":"Uygun","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib71","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.clinre.2013.05.005","article-title":"What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study","volume":"37","author":"Onal","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib72","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejim.2013.11.006","article-title":"Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments","volume":"25","author":"Sapmaz","year":"2014","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.gtc.2015.05.003_bib73","first-page":"271","article-title":"Helicobacter pylori eradication in renal recipient: triple or quadruple therapy?","volume":"52","author":"Hosseini","year":"2014","journal-title":"Acta Med Iran"},{"key":"10.1016\/j.gtc.2015.05.003_bib74","first-page":"9","article-title":"Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter pylori infection","volume":"5","author":"Talaie","year":"2014","journal-title":"J\u00a0Paramedical Sci"},{"key":"10.1016\/j.gtc.2015.05.003_bib75","first-page":"87","article-title":"Antibiotic resistance in Helicobacter pylori infection","volume":"11","author":"Goral","year":"2000","journal-title":"T\u00a0Klin J Gastroenterohepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib76","first-page":"987","article-title":"Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran","volume":"49","author":"Abadi","year":"2011","journal-title":"J\u00a0Microbiol"},{"key":"10.1016\/j.gtc.2015.05.003_bib77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12098-007-0003-4","article-title":"Helicobacter pylori culture and antimicrobial resistance in Iran","volume":"74","author":"Fallahi","year":"2007","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.gtc.2015.05.003_bib78","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3748\/wjg.v16.i45.5746","article-title":"Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran","volume":"16","author":"Farshad","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib79","first-page":"1056","article-title":"Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran","volume":"18","author":"Khademi","year":"2013","journal-title":"J\u00a0Res Med Sci"},{"key":"10.1016\/j.gtc.2015.05.003_bib80","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s10156-012-0425-4","article-title":"The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics","volume":"18","author":"Milani","year":"2012","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.gtc.2015.05.003_bib81","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3748\/wjg.v11.i38.6009","article-title":"Helicobacter pylori antibiotic resistance in Iran","volume":"11","author":"Mohammadi","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/1319-3767.82581","article-title":"Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran","volume":"17","author":"Shokrzadeh","year":"2011","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib83","first-page":"308","article-title":"Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children","volume":"9","author":"Siavoshi","year":"2006","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.gtc.2015.05.003_bib84","first-page":"177","article-title":"Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline\u2013comparison of three 3-year studies","volume":"13","author":"Siavoshi","year":"2010","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.gtc.2015.05.003_bib85","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11739-011-0563-1","article-title":"Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran","volume":"7","author":"Talebi Bezmin","year":"2012","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.gtc.2015.05.003_bib86","first-page":"336","article-title":"Antibiotic resistance of Helicobacter pylori in Mashhad, Iran","volume":"63","author":"Zendedel","year":"2013","journal-title":"J\u00a0Pak Med Assoc"},{"key":"10.1016\/j.gtc.2015.05.003_bib87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","article-title":"Treatment of Helicobacter pylori infection: a review of the world literature","volume":"1","author":"van der Hulst","year":"1996","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib88","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2003.01653.x","article-title":"Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori","volume":"18","author":"Chi","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib89","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1440-1746.2006.04291.x","article-title":"Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in\u00a0vitro susceptibility","volume":"21","author":"Cheon","year":"2006","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib90","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4318\/tjg.2012.0392","article-title":"Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori","volume":"23","author":"Kadayifci","year":"2012","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/gut.35.1.15","article-title":"One week's anti-Helicobacter pylori treatment for duodenal ulcer","volume":"35","author":"Logan","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2015.05.003_bib92","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0149-2918(97)80044-6","article-title":"High eradication rate of Helicobacter pylori using a four-drug regimen in patients previously treated unsuccessfully","volume":"19","author":"Tzivras","year":"1997","journal-title":"Clin Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib93","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1523-5378.2012.00989.x","article-title":"Efficacy of a modified sequential therapy including bismuth subcitrate as first-line therapy to eradicate Helicobacter pylori in a Turkish population","volume":"17","author":"Uygun","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib94","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1523-5378.2011.00844.x","article-title":"Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy","volume":"16","author":"Chung","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib95","first-page":"246","article-title":"The trends of one-week first-line and second-line eradication therapy for Helicobacter pylori infection in Korea","volume":"58","author":"Chung","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gtc.2015.05.003_bib96","first-page":"368","article-title":"Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication","volume":"46","author":"Jang","year":"2005","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib97","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1523-5378.2011.00870.x","article-title":"Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy","volume":"16","author":"Lee","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.gtc.2015.05.003_bib98","first-page":"136","article-title":"Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection","volume":"44","author":"Park","year":"2004","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib99","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00042737-200605000-00010","article-title":"Long-term outcomes after Helicobacter pylori eradication with second-line, bismuth-containing quadruple therapy in Korea","volume":"18","author":"Cheon","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5009\/gnl.2012.6.4.434","article-title":"Comparison of the eradication rate between 1- and 2-week bismuth-containing quadruple rescue therapies for Helicobacter pylori eradication","volume":"6","author":"Yoon","year":"2012","journal-title":"Gut Liver"},{"key":"10.1016\/j.gtc.2015.05.003_bib101","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.3748\/wjg.v18.i45.6628","article-title":"Trends in the eradication rates of Helicobacter pylori infection for eleven years","volume":"18","author":"Yoon","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib102","first-page":"1293","article-title":"Eradication rates of Helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease","volume":"54","author":"Chung","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gtc.2015.05.003_bib103","doi-asserted-by":"crossref","DOI":"10.5009\/gnl14020","article-title":"Efficacy of 7-day and 14-day bismuth-containing quadruple therapy and 7-day and 14-day moxifloxacin-based triple therapy as second-line eradication for Helicobacter pylori infection","author":"Lee","year":"2015","journal-title":"Gut Liver"},{"key":"10.1016\/j.gtc.2015.05.003_bib104","first-page":"60","article-title":"A\u00a01-h topical therapy for the treatment of Helicobacter pylori infection","volume":"90","author":"Kimura","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2015.05.003_bib105","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2036.1994.tb00321.x","article-title":"Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori. Assessment of the importance of antibiotic dose timing in relation to meals","volume":"8","author":"Atherton","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib106","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2036.1996.37179000.x","article-title":"Enhanced eradication of Helicobacter pylori by pre- versus post- prandial amoxycillin suspension with omeprazole: implications for antibiotic delivery","volume":"10","author":"Atherton","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2015.05.003_bib107","first-page":"1134","article-title":"Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China","volume":"25","author":"Lu","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib108","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cgh.2008.10.024","article-title":"Efficient identification and evaluation of effective Helicobacter pylori therapies","volume":"7","author":"Graham","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.05.003_bib109","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1574-6968.2001.tb10572.x","article-title":"Identification of genes regulated by prolonged acid exposure in Helicobacter pylori","volume":"196","author":"Dong","year":"2001","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.gtc.2015.05.003_bib110","first-page":"34","article-title":"Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance","volume":"76","author":"Koksal","year":"2013","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.gtc.2015.05.003_bib111","first-page":"CR193","article-title":"Eradication rate of Helicobacter pylori in dyspeptic patients","volume":"11","author":"Amini","year":"2005","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.gtc.2015.05.003_bib112","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejim.2008.04.003","article-title":"The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication","volume":"20","author":"Akyildiz","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.gtc.2015.05.003_bib113","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MAJ.0b013e31821fc2aa","article-title":"Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori","volume":"342","author":"Hu","year":"2011","journal-title":"Am J Med Sci"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855315000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855315000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T17:10:47Z","timestamp":1599153047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855315000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0889855315000497"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2015.05.003","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Effectively Use Bismuth Quadruple Therapy","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2015.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}